NCT02275585

Portal Vein Thrombosis in Cirrhosis

Portal Vein Thrombosis in Cirrhosis: A Cohort Sudy

• Status: Withdrawn
• Phase: —
• Study type: Observational
• Enrollment: 0 (actual)
• Sponsor: Corporacion Parc Tauli · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the supervivence of cirrhotic patients that develop portal vein thrombosis in comparison to cirrhotic patients that do not develop portal vein thrombosis.

Detailed description

Patients newly diagnosed with portal vein thrombosis by imaging tests, that evaluate the extent and exclude tumoral origin, will be included (informed consent previously signed). Anticoagulant treatment will be initiated according to clinical guidelines (if there is no contraindication) first with LMWH (low molecular weight heparin) and later with dicoumarin. An abdominal CT will be performed to evaluate the extent and exclude tumoral origin; a gastroscopy to evaluate portal hypertension (and do prophylaxis if required) and thrombophilia study. Patients will be followed by imaging and laboratory tests every 6 months; to evaluate the response to the treatment and detect any cirrhosis complication.

Conditions

• Hepatic Vein Thrombosis
• Cirrhosis

Interventions

Type	Name	Description
OTHER	Event of portal vein thrombosis	There is no intervention over patients. They are followed during 3 years to look after any event of portal vein thrombosis

Timeline

• Start date: 2013-10-01
• Primary completion: 2014-01-01
• Completion: 2014-10-01
• First posted: 2014-10-27
• Last updated: 2017-08-09